MarketCap
XTL Biopharmaceuticals Ltd. XTLB
$ 1.66
-6.74%
Facebook
X
Telegram
XTL Biopharmaceuticals Ltd. DSO Ratio | XTLB
Annual DSO Ratio XTL Biopharmaceuticals Ltd.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | 65.6 | 49 | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 65.6 | 49 | 57.3 |
DSO Ratio of other stocks in the Biotechnology industry
| Issuer | DSO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Repare Therapeutics
RPTX
|
16.7 K | - | - | $ 112 M |  Canada |
 |
Sesen Bio
SESN
|
391 | - | 7.29 % | $ 127 M |  USA |
 |
Windtree Therapeutics
WINT
|
93.6 | - | - | $ 26.8 M | USA |
 |
SQZ Biotechnologies Company
SQZ
|
25.5 | - | 57.95 % | $ 12.8 M | USA |
 |
MEI Pharma
MEIP
|
392 | - | 10.43 % | $ 20.5 M | USA |
 |
Palatin Technologies
PTN
|
6.22 | - | - | $ 13 M | USA |
 |
Brickell Biotech
BBI
|
26 | - | -5.38 % | $ 6.06 M | USA |
 |
Generation Bio Co.
GBIO
|
47.6 | - | - | $ 344 M | USA |
 |
Clearside Biomedical
CLSD
|
107 | - | - | $ 25.3 M | USA |
 |
Merus N.V.
MRUS
|
18.6 | - | - | $ 5.78 B |  Niderland |
 |
AbbVie
ABBV
|
258 | $ 294.72 | 0.32 % | $ 521 B | USA |
 |
Galmed Pharmaceuticals Ltd.
GLMD
|
33.4 | $ 4.63 | 21.05 % | $ 20 M |  Israel |
 |
Achieve Life Sciences
ACHV
|
36.8 | $ 6.78 | 0.89 % | $ 296 M | USA |
 |
Axon Enterprise
AXON
|
134 | $ 316.97 | 4.77 % | $ 24.7 B | USA |
 |
Bristol-Myers Squibb Company
BMY
|
83.9 | $ 62.89 | 0.18 % | $ 128 B | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
2.33 | - | -15.15 % | $ 60.3 M |  Britain |
 |
Cytokinetics, Incorporated
CYTK
|
71.3 | $ 58.59 | 4.29 % | $ 7.04 M | USA |
 |
Dynavax Technologies Corporation
DVAX
|
56.5 | - | - | $ 2.02 B | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
43.3 | $ 159.75 | 5.35 % | $ 20.9 B | USA |
 |
Amgen
AMGN
|
81.2 | $ 467.97 | 0.59 % | $ 252 B | USA |
 |
Orgenesis
ORGS
|
22.6 | - | -33.86 % | $ 61.2 M | USA |
 |
Jazz Pharmaceuticals plc
JAZZ
|
66.2 | $ 248.31 | 1.17 % | $ 15.1 B |  Irlanda |
 |
Johnson & Johnson
JNJ
|
62 | $ 280.31 | -0.17 % | $ 675 B | USA |
 |
Kala Pharmaceuticals
KALA
|
729 | $ 0.17 | 0.64 % | $ 1.39 M | USA |
 |
Sage Therapeutics
SAGE
|
408 | - | - | $ 527 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
28.1 | $ 1.59 | -2.76 % | $ 2.62 M | Israel |
 |
Lineage Cell Therapeutics
LCTX
|
19.2 | $ 1.13 | 8.17 % | $ 260 M | USA |
 |
Paratek Pharmaceuticals
PRTK
|
119 | - | - | $ 121 M | USA |
 |
C4 Therapeutics
CCCC
|
27.9 | $ 2.9 | -3.5 % | $ 240 M | USA |
 |
Eli Lilly and Company
LLY
|
80.5 | $ 1 437.4 | 0.36 % | $ 1.29 T | USA |
 |
Compugen Ltd.
CGEN
|
400 | $ 2.09 | -0.24 % | $ 195 M | Israel |
 |
Adverum Biotechnologies
ADVM
|
222 | - | - | $ 86.2 M | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
211 | $ 84.95 | 0.13 % | $ 7.99 B | USA |